Shares in Intersect ENT (NSDQ:XENT) fell today even though the medical device maker topped expectations on Wall Street with its third-quarter financial results.
The Menlo Park, Calif.-based company posted a net loss of -$7.6 million on sales of $24.7 million for the 3 months ended Sept. 30, for sales growth of 11% compared with the same period last year.
Get the full story at our sister site, Drug Delivery Business News.
The post Intersect ENT tops estimates with Q3 results appeared first on MassDevice.